13 Lung Cancer Clinical Trials in Jonesboro, AR (2026)

Q: How do I join a clinical trial in Jonesboro?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Jonesboro research site will contact you.

Recruiting Lung Cancer Studies in Jonesboro

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Jonesboro, ARPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT06632327Recruiting

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell ...

Jonesboro, ARPHASE31,100 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT07217301Recruiting

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from...

Jonesboro, ARPHASE3600 participantsTakeda

View Study Details

NCT06538038Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Grow...

Jonesboro, AR538 participantsPrECOG, LLC.

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Jonesboro, ARPHASE3474 participantsNRG Oncology

View Study Details

NCT06616584Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

Jonesboro, ARPHASE2378 participantsSWOG Cancer Research Network

View Study Details

NCT07005128Recruiting

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolon...

Jonesboro, ARPHASE3330 participantsAmgen

View Study Details

NCT06498635Recruiting

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclo...

Jonesboro, ARPHASE3306 participantsNational Cancer Institute (NCI)

View Study Details

NCT04181060Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage II...

Jonesboro, ARPHASE3300 participantsNational Cancer Institute (NCI)

View Study Details

NCT04402788Recruiting

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab ...

Jonesboro, ARPHASE2138 participantsNational Cancer Institute (NCI)

View Study Details

NCT06116682Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a ...

Jonesboro, ARPHASE288 participantsSWOG Cancer Research Network

View Study Details

NCT05642572Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...

Jonesboro, ARPHASE266 participantsSWOG Cancer Research Network

View Study Details

NCT06031688Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first s...

Jonesboro, ARPHASE256 participantsSWOG Cancer Research Network

View Study Details

About Lung Cancer Clinical Trials in Jonesboro

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 13 lung cancer clinical trials recruiting participants in Jonesboro, AR. These studies are seeking a combined 5,584 participants. Research is being sponsored by National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, Takeda and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Jonesboro — FAQ

Are there lung cancer clinical trials in Jonesboro?

Yes, there are 13 lung cancer clinical trials currently recruiting in Jonesboro, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Jonesboro?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jonesboro research site will contact you about next steps.

Are clinical trials in Jonesboro free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jonesboro studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 13 active trials in Jonesboro are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 17, 2026 from ClinicalTrials.gov